See more : Fancl Corporation (4921.T) Income Statement Analysis – Financial Results
Complete financial analysis of Adicet Bio, Inc. (ACET) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adicet Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TRON Group Inc. (TGRP) Income Statement Analysis – Financial Results
- Arbutus Biopharma Corporation (ABUS) Income Statement Analysis – Financial Results
- Broad Enterprise Co.,Ltd. (4415.T) Income Statement Analysis – Financial Results
- PT Bakrieland Development Tbk (ELTY.JK) Income Statement Analysis – Financial Results
- Cyfrowy Polsat S.A. (CYFWF) Income Statement Analysis – Financial Results
Adicet Bio, Inc. (ACET)
About Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 24.99M | 9.73M | 17.90M | 995.00K | 8.18M | 558.52M | 546.95M | 510.18M | 499.69M | 499.69M | 444.39M | 412.43M | 346.63M | 322.65M | 359.59M |
| Cost of Revenue | 6.10M | 5.01M | 0.00 | 0.00 | 125.00K | 80.00K | 5.00K | 411.52M | 395.48M | 401.42M | 401.42M | 362.36M | 346.59M | 292.48M | 267.03M | 292.29M |
| Gross Profit | -6.10M | 19.98M | 9.73M | 17.90M | 870.00K | 8.10M | 558.52M | 135.43M | 114.70M | 98.27M | 98.27M | 82.03M | 65.84M | 54.16M | 55.62M | 67.31M |
| Gross Profit Ratio | 0.00% | 79.96% | 100.00% | 100.00% | 87.44% | 99.02% | 100.00% | 24.76% | 22.48% | 19.67% | 19.67% | 18.46% | 15.96% | 15.62% | 17.24% | 18.72% |
| Research & Development | 106.04M | 71.25M | 48.94M | 34.33M | 23.69M | 14.72M | 16.84M | 5.94M | 5.22M | 2.83M | 0.00 | 0.00 | 0.00 | 0.00 | 153.00K | 506.00K |
| General & Administrative | 26.53M | 26.30M | 22.22M | 22.76M | 8.69M | 8.43M | 76.82M | 73.16M | 65.21M | 61.02M | 63.86M | 56.67M | 49.29M | 44.72M | 43.57M | 45.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -74.78M | -73.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.53M | 26.30M | 22.22M | 22.76M | 8.69M | 8.43M | 2.04M | 1.00K | 65.21M | 61.02M | 63.86M | 56.67M | 49.29M | 44.72M | 43.57M | 45.42M |
| Other Expenses | 19.46M | -919.00K | -606.00K | -953.00K | 2.33M | 4.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 152.04M | 97.54M | 71.16M | 57.09M | 32.38M | 23.15M | 18.88M | 1.00K | 70.43M | 63.86M | 63.86M | 56.67M | 49.29M | 44.72M | 43.73M | 45.93M |
| Cost & Expenses | 152.04M | 97.54M | 71.16M | 57.09M | 32.38M | 23.15M | 18.88M | 1.00K | 465.91M | 465.27M | 465.27M | 419.02M | 395.88M | 337.19M | 310.75M | 338.21M |
| Interest Income | 9.95M | 3.76M | 91.00K | 785.00K | 938.00K | 543.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 80.00K | 176.00K | 134.00K | 0.00 | 0.00 | 7.00M | 3.95M | 2.10M | 2.12M | 2.12M | 2.63M | 1.57M | 230.00K | 98.00K | 145.00K |
| Depreciation & Amortization | 6.10M | 5.01M | 4.07M | 1.95M | 1.24M | 80.00K | 5.00K | 11.85M | 8.09M | 6.94M | 6.94M | 6.94M | 5.50M | 2.80M | 1.87M | 2.38M |
| EBITDA | -136.54M | -64.70M | -60.41M | -37.41M | -26.88M | -13.74M | -33.77M | -1.00K | 54.87M | 43.62M | 43.62M | 34.31M | 24.03M | 13.23M | 14.70M | 24.71M |
| EBITDA Ratio | 0.00% | -278.95% | -636.67% | -219.85% | -2,701.61% | -105.93% | -3.38% | 0.00% | 10.75% | 8.73% | 8.73% | 7.72% | 5.83% | 3.82% | 4.55% | 6.87% |
| Operating Income | -152.04M | -72.55M | -61.43M | -39.19M | -31.39M | -14.96M | -18.88M | -1.00K | 44.27M | 34.42M | 34.42M | 25.37M | 16.55M | 9.44M | 11.89M | 21.38M |
| Operating Income Ratio | 0.00% | -290.32% | -631.38% | -218.91% | -3,154.57% | -182.91% | -3.38% | 0.00% | 8.68% | 6.89% | 6.89% | 5.71% | 4.01% | 2.72% | 3.69% | 5.94% |
| Total Other Income/Expenses | 9.38M | 2.76M | -691.00K | -302.00K | 3.27M | 5.08M | -14.90M | 0.00 | 402.00K | 134.00K | 134.00K | -626.00K | 412.00K | 765.00K | 839.00K | 812.00K |
| Income Before Tax | -142.66M | -69.79M | -62.12M | -39.49M | -28.12M | -9.89M | -33.78M | -1.00K | 44.67M | 34.55M | 34.55M | 24.74M | 16.96M | 10.20M | 12.73M | 22.19M |
| Income Before Tax Ratio | 0.00% | -279.27% | -638.48% | -220.59% | -2,826.03% | -120.87% | -6.05% | 0.00% | 8.76% | 6.91% | 6.91% | 5.57% | 4.11% | 2.94% | 3.95% | 6.17% |
| Income Tax Expense | 0.00 | -2.76M | -125.00K | -2.82M | 19.00K | -589.00K | 19.09M | 20.38M | 15.67M | 12.22M | 12.22M | 7.76M | 7.99M | 3.62M | 4.10M | 8.72M |
| Net Income | -142.66M | -67.03M | -62.00M | -36.68M | -28.14M | -9.30M | -33.78M | -1.00K | 29.00M | 22.33M | 22.33M | 16.98M | 8.97M | 6.58M | 8.63M | 13.47M |
| Net Income Ratio | 0.00% | -268.22% | -637.19% | -204.87% | -2,827.94% | -113.67% | -6.05% | 0.00% | 5.68% | 4.47% | 4.47% | 3.82% | 2.17% | 1.90% | 2.67% | 3.75% |
| EPS | -3.31 | -1.63 | -2.00 | -5.01 | -1.52 | -0.31 | -1.26 | 0.00 | 1.18 | 0.94 | 0.94 | 0.73 | 0.40 | 0.30 | 0.40 | 0.63 |
| EPS Diluted | -3.31 | -1.63 | -2.00 | -5.01 | -1.52 | -0.31 | -1.25 | 0.00 | 1.16 | 0.93 | 0.93 | 0.72 | 0.39 | 0.30 | 0.39 | 0.62 |
| Weighted Avg Shares Out | 43.04M | 41.08M | 30.95M | 7.32M | 18.56M | 29.80M | 26.77M | 28.05M | 24.50M | 23.67M | 23.67M | 23.26M | 22.67M | 21.86M | 21.43M | 21.30M |
| Weighted Avg Shares Out (Dil) | 43.04M | 41.08M | 30.95M | 7.32M | 18.56M | 29.80M | 26.97M | 28.05M | 24.99M | 24.02M | 24.02M | 23.46M | 22.84M | 22.07M | 21.86M | 21.70M |
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present...
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Misses Revenue Estimates
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 5.36% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Adicet Bio to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two...
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Misses Revenue Estimates
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -24.44% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
7 Cheap Biotech Stocks to Buy Now
Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.
Adicet Bio to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in three...
Adicet Bio: A First Take
Today, we take a look at Adicet Bio for the first time. The company is pioneering what it hopes will be among the next wave of CAR-T therapies and is advancing its lead candidate.
Adicet Bio, Inc. (ACET) Is a Great Choice for "Trend" Investors, Here's Why
Adicet Bio, Inc. (ACET) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Catalyst Biosciences, Inc. (CBIO) have performed compared to their sector so far this year.
Source: https://incomestatements.info
Category: Stock Reports